Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109719 | 1.00 | SCD (0.39) | SCDHTR2CHTR2AHTR1AHTR1D | |
| SCHEMBL24109704 | 0.88 | HTR2A (0.38) | SCDHTR2CHTR2AHTR7SCN9A | |
| SCHEMBL24110275 | 0.87 | SCD (0.41) | SCDHTR2CHTR2AHTR1AHTR1D | |
| SCHEMBL24110263 | 0.84 | HTR2A (0.43) | HTR2CHTR2ASCN9A | |
| SCHEMBL25820515 | 0.84 | HTR2A (0.43) | HTR2CHTR2ASCN9A | |
| SCHEMBL24109741 | 0.84 | HTR2A (0.37) | SCDHTR2CHTR2AHTR7 | |
| SCHEMBL24110198 | 0.80 | SCN9A (0.37) | HTR2CHTR2ASCN9A | |
| SCHEMBL24110294 | 0.80 | SCN9A (0.35) | HTR2CHTR2ASCN9A | |
| SCHEMBL24109720 | 0.80 | HTR2A (0.47) | SCDHTR2CHTR2AHTR7ROCK1 | |
| SCHEMBL25825463 | 0.80 | HTR2A (0.47) | SCDHTR2CHTR2AHTR7ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | SCD 1360/4885HTR2C 35/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.